Joaquin Mateo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joaquin Mateo has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Anna Oliveira Tercero
10Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron University Hospital, Barcelona, Spain
66 shared publications - Laura Agundez Muriel
10Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron University Hospital, Barcelona, Spain
66 shared publications - Johann Sebastian de Bono
The Royal Marsden NHS Foundation Trust, London, United Kingdom
59 shared publications - Abel González-Pérez
Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain
49 shared publications - Alexander William Wyatt
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
49 shared publications - Eliezer Mendel Van Allen
Broad Institute of MIT and Harvard, Cambridge, USA
49 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Springer Nature in Nature Medicine
- p. 1-12
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
- 14 October 2026
- Published by Springer Nature in Nature Medicine
- p. 1-12
Open AccessTalazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial
- Open Access
- 2 October 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (10) , 1043
Correction to: Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN registry
- 2 October 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (10) , 1043
Open AccessCorrection to: Prevalence of meeting aerobic physical activity and resistance training guidelines in advanced prostate cancer: a descriptive study of racial and regional disparities in the IRONMAN registry
- Open Access
The RNA cargo of plasma-derived extracellular vesicles in mCRPC patients captures cancer cells and tumor microenvironment signals
Circulating analytes in cancer patients capture tumor-related signals. We profiled matched extracellular vesicle (EV) total RNA and cell-free DNA (cfDNA) from the same plasma aliquots of chemo-naive metastatic castration-resistant prostate cancer (mCRPC) patients treated with Enzalutamide (n=54 patients, n=119 longitudinal samples; NCT06981377 ) at four Italian clinical centers and interrogated data from >10,000 cancer patients’ and healthy individuals’ samples. Transcript integrity analysis identified coding and non-coding species with fragmentation patterns varying across RNA biotypes. EV-RNA data deconvolution revealed signal from immune populations, including fractions classified as CD4+ T cells, whose abundance increased with disease progression in plasma EVs and mCRPC tissues. By leveraging tissue data-informed mining, we established a novel prostate cancer-related EV-RNA signature that resulted in an independent predictor of poor prognosis and captured tumor microenvironment-derived signals. Integrating EV-RNA and ctDNA information improved patient stratification for progression-free survival. These findings suggest a multifaceted role for plasma EVs as a source of cancer biomarkers. Statement of significance: EV-RNA provides biologically relevant tumor and immune-derived signals in mCRPC. Integration with cfDNA improves patient stratification, highlighting EVs as a complementary source of translational information for monitoring disease progression and therapeutic response in prostate cancer.
Open AccessThe RNA cargo of plasma-derived extracellular vesicles in mCRPC patients captures cancer cells and tumor microenvironment signals
Circulating analytes in cancer patients capture tumor-related signals. We profiled matched extracellular vesicle (EV) total RNA and cell-free DNA (cfDNA) from the same plasma aliquots of chemo-naive metastatic castration-resistant prostate cancer (mCRPC) patients treated with Enzalutamide (n=54 patients, n=119 longitudinal samples; NCT06981377 ) at four Italian clinical centers and interrogated data from >10,000 cancer patients’ and healthy individuals’ samples. Transcript integrity analysis identified coding and non-coding species with fragmentation patterns varying across RNA biotypes. EV-RNA data deconvolution revealed signal from immune populations, including fractions classified as CD4+ T cells, whose abundance increased with disease progression in plasma EVs and mCRPC tissues. By leveraging tissue data-informed mining, we established a novel prostate cancer-related EV-RNA signature that resulted in an independent predictor of poor prognosis and captured tumor microenvironment-derived signals. Integrating EV-RNA and ctDNA information improved patient stratification for progression-free survival. These findings suggest a multifaceted role for plasma EVs as a source of cancer biomarkers. Statement of significance: EV-RNA provides biologically relevant tumor and immune-derived signals in mCRPC. Integration with cfDNA improves patient stratification, highlighting EVs as a complementary source of translational information for monitoring disease progression and therapeutic response in prostate cancer.
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Immunogenicity and cross reactivity of CD8+ T transduced with specific AR H875Y TCRs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Immunogenicity and cross reactivity of CD8+ T transduced with specific AR H875Y TCRs
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Single Cell TCRseq of donor 157 with AR H875Y 9-mer dextramer staining sorted T-cells
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Single Cell TCRseq of donor 157 with AR H875Y 9-mer dextramer staining sorted T-cells
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-B*15:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-B*15:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Synthetic peptides used in this study
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Synthetic peptides used in this study
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y T157.2 TCR reactivity in healthy donor PBMCs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y T157.2 TCR reactivity in healthy donor PBMCs
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y TCR cytotoxicity in healthy donor PBMCs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y TCR cytotoxicity in healthy donor PBMCs
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-A*01:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-A*01:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation